Table 1. Primary location of non-procedure-related bleeding in the PLATO study.

	Ticagrelor (n = 9,235)	Clopidogrel (n = 9,186)
Any spontaneous major bleeding
Patients	235	180
Events	664	483
Primary location of bleeding, numbers of events (%)
Gastrointestinal	209 (31.5)	178 (36.9)
Epistaxis	133 (20.0)	70 (14.5)
Urinary	58 (8.7)	54 (11.2)
Subcutaneous/dermal	64 (9.6)	44 (9.1)
Intracranial	36 (5.4)	18 (3.7)
Pericardial	15 (2.3)	15 (3.1)
Hemoptysis	16 (2.4)	11 (2.3)
Intraocular	3 (0.5)	4 (0.8)
Retroperitoneal	4 (0.6)	3 (0.6)
Intra-articular	2 (0.3)	1 (0.2)
Cardiac catheterization/PCI access site	2 (0.3)	0 (0.0)
Other bleeding site	122 (18.4)	85 (17.6)

Adapted and modified from reference 20. PCI, percutaneous coronary intervention.